Implementation of Genetics to Personalize Medicine

Gender Medicine

Volumn 4, Issue 3, 2007, Pages 248-265

  Chung, Wendy K ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

genetic; genomic; personalized medicine; pharmacogenomics; risk stratification

Indexed keywords

AROMATASE INHIBITOR; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; DRUG METABOLIZING ENZYME; FLUOROURACIL; IRINOTECAN; MERCAPTOPURINE; NEUROLEPTIC AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ARTICLE; BLEEDING; BREAST CANCER; CANCER RISK; CLINICAL MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG METABOLISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; GERM LINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMOCHROMATOSIS; HUMAN; LONG QT SYNDROME; MATURITY ONSET DIABETES MELLITUS; MEDICAL ETHICS; MEDLINE; MOLECULAR GENETICS; NEWBORN SCREENING; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; REIMBURSEMENT; RISK ASSESSMENT; VALIDATION PROCESS;

BIOMEDICAL RESEARCH; BIOTECHNOLOGY; FORECASTING; GENETIC SCREENING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; PHARMACOGENETICS; UNITED STATES; VARIATION (GENETICS);

EID: 36048935611     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1550-8579(07)80044-1     Document Type: Article

References (92)

1. University of Washington. GeneTests. Available at:. http://www.genetests.org/
2. Edwards A., Ritter III R., Abel K., et al. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
3. Haines J., Hauser M., Schmidt S., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
4. Klein R., Zeiss C., Chew E., et al. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
5. Yates J., Sepp T., Matharu B., et al., Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357 (2007) 553-561
6. Saxena R., Voight B., Lyssenko V., et al., Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 (2007) 1331-1336
7. Scott L., Mohlke K., Bonnycastle L., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 (2007) 1341-1345
8. Zeggini E., Weedon M., Lindgren C., et al. Repli- cation of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316 (2007) 1336-1341
9. Frayling T., Timpson N., Weedon M., et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316 (2007) 889-894
10. Hamet P., and Seda O. Current status of genome-wide scanning for hypertension. Curr Opin Cardiol 22 (2007) 292-297
11. McPherson R., Pertsemlidis A., Kavaslar N., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316 (2007) 1488-1491
12. Duerr R., Taylor K., Brant S., et al. A genome- wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
13. Hampe J., Franke A., Rosenstiel P., et al. A genome- wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn dis- ease in ATG16L1. Nat Genet 39 (2007) 207-211
14. Easton D., Pooley K., Dunning A., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 (2007) 1087-1093
15. Coon K., Myers A., Craig D., et al. A high- density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68 (2007) 613-618
16. Verhoog L., Brekelmans C., Seynaeve C., et al. Survival and tumour characteristics of breast- cancer patients with germline mutations of BRCA 1. Lancet 351 (1998) 316-321
17. Kauff N., Mitra N., Robson M., et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation- negative hereditary breast cancer families. J Natl Cancer Inst 97 (2005) 1382-1384
18. Schwartz P., Priori S., Spazzolini C., et al. Genotype- phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhyth- mias. Circulation 103 (2001) 89-95
19. Moss A., Windle J., Hall W., et al. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): A randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 10 Suppl 4 (2005) 59-66
20. Codner E., Deng L., Perez-Bravo F., et al. Glucokinase mutations in young children with hyperglyce- mia. Diabetes Metab Res Rev 22 (2006) 348-355
21. Pearson E., Starkey B., Powell R., et al. Genetic cause of hyperglycaemia and response to treat- ment in diabetes. Lancet 362 (2003) 1275-1281
22. Jazwinska E., Cullen L., Busfield F., et al. Haemochromatosis and HLA-H. Nat Genet 14 (1996) 249-251
23. Beutler E., Felitti V., Koziol J., et al. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
24. Grant S., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38 (2006) 320-323
25. Florez J., Jablonski K., Bayley N., et al., Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355 (2006) 241-250
26. Marsden D., Larson C., and Levy H. Newborn screening for metabolic disorders. J Pediatr 148 (2006) 577-584
27. National Newborn Screening & Genetics Resource Center. National newborn screening status report. Available at. http://genes-r-us.uthscsa.edu/nbsdisorders.pdf
28. Blois B., Riddell C., Dooley K., and Dyack S. Newborns with C8-acylcarnitine level over the 90th centile have an increased frequency of the common MCAD 985A>G mutation. J Inherit Metab Dis 28 (2005) 551-556
29. Kosel S., Burggraf S., Fingerhut R., et al. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem 51 (2005) 298-304
30. Wilcken B. Newborn screening for cystic fibrosis: Techniques and strategies. J Inherit Metab Dis 30 (2007) 537-543
31. Health Resources and Services Administration. Newborn screening: Toward a uniform screening panel and system. Available at:. http://mchb.hrsa.gov/screening/
32. Wilson J., and Jungner Y. Principles and practice of mass screening for disease [in Spanish]. Bol Oficina Sanit Panam 65 (1968) 281-393
33. McGhee S., Stiehm E., Cowan M., et al. Two-tiered universal newborn screening strategy for severe combined immunodeficiency. Mol Genet Metab 86 (2005) 427-430
34. Moser H., Mahmood A., and Raymond G. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 3 (2007) 140-151
35. Watson M. Current status of newborn screening: Decision-making about the conditions to include in screening programs. Ment Retard Dev Disabil Res Rev 12 (2006) 230-235
36. Green N., and Pass K. Neonatal screening by DNA microarray: Spots and chips. Nat Rev Genet 6 (2005) 147-151
37. Acharya K., Ackerman P., and Ross L. Pediatricians' attitudes toward expanding newborn screening. Pediatrics 116 (2005) e476-e484
38. Waisbren S., Albers S., Amato S., et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290 (2003) 2564-2572
39. Haga S., and Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 291 (2004) 2869-2871
40. Wysowski D., Nourjah P., and Swartz L. Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med 167 (2007) 1414-1419
41. Aquilante C., Langaee T., Lopez L., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79 (2006) 291-302
42. Carlquist J., Home B., Muhlestein J., et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: A prospective study. J Thromb Thrombolysis 22 (2006) 191-197
43. ClinicalTrials.gov. A pharmacogenetic study of warfarin dosing, "The COUMA-GEN Study.". Available at:. http://clinicaltrial.gov/ct/show/NCTOO334464?order=1
44. ClinicalTrials.gov. Modeling genotype and other factors to enhance the safety of coumadin prescribing. Available at. http://clinicaltrial.gov/ct/show/NCTOO484640?order=1
45. Gonzalez F., and Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci 16 (1995) 325-327
46. Iyer L., King C., Whitington P., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101 (1998) 847-854
47. Tai H., Krynetski E., Yates C., et al. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58 (1996) 694-702
48. Ulrich C., Yasui Y., Storb R., et al. Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98 (2001) 231-234
49. Goetz M., Knox S., Suman V., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 (2007) 113-121
50. Lynch T., Bell D., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
51. Buckhaults P. Gene expression determinants of clinical outcome. Curr Opin Oncol 18 (2006) 57-61
52. Starling R., Pham M., Valantine H., et al., Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: Initial clinical experience. [published correction appears in J Heart Lung Transplant. 2007;26:204]. J Heart Lung Transplant 25 (2006) 1389-1395
53. Sundseth S., Alberta J., and Waxman D. Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes. J Biol Chem 267 (1992) 3907-3914
54. Yang X., Schadt E., Wang S., et al. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 16 (2006) 995-1004
55. Redon R., Ishikawa S., Fitch K., et al. Global variation in copy number in the human genome. Nature 444 (2006) 444-454
56. de Vries B., Pfundt R., Leisink M., et al. Diagnostic genome profiling in mental retardation. Am J Hum Genet 77 (2005) 606-616
57. Schoumans J., Ruivenkamp C., Holmberg E., et al. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). J Med Genet 42 (2005) 699-705
58. Sebat J., Lakshmi B., Malhotra D., et al. Strong association of de novo copy number mutations with autism. Science 316 (2007) 445-449
59. Sebat J., Lakshmi B., Troge J., et al. Large-scale copy number polymorphism in the human genome. Science 305 (2004) 525-528
60. Pinkel D., and Albertson D. Comparative genomic hybridization. Annu Rev Genomics Hum Genet 6 (2005) 331-354
61. Zogopoulos G., Ha K., Naqib F., et al. Germ-line DNA copy number variation frequencies in a large North American population. Hum Genet. Epub (July 19, 2007)
62. Elson J., Samuels D., Turnbull D., and Chinnery P. Random intracellular drift explains the clonal expansion of mitochondrial DNA mutations with age. Am J Hum Genet 68 (2001) 802-806
63. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678
64. Antoniou A., Pharoah P., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. [published correction appears in Am J Hum Genet. 2003;73:709]. Am J Hum Genet. 72 (2003) 1117-1130
65. Hartge P., Struewing J., Wacholder S., et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64 (1999) 963-970
66. Rosendaal F. Venous thrombosis: A multicausal disease. Lancet 353 (1999) 1167-1173
67. Vandenbroucke J., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
68. Collins F., Green E., Guttmacher A., Guyer M., and National Human Genome Research Institute. A vision for the future of genomics research. Nature 422 (2003) 835-847
69. Korf B., Feldman G., and Wiesner G. Report of Banbury Summit meeting on training of physicians in medical genetics, October 20-22, 2004. Genet Med 7 (2005) 433-438
70. US Public Health Service. My family health portrait. Available at. https://familyhistory.hhs.gov/
71. Wilkins-Haug L., Hill L., Power M., et al. Gynecologists' training, knowledge, and experiences in genetics: A survey. Obstet Gynecol 95 (2000) 421-424
72. Wilkins-Haug L., Erickson K., Hill L., et al. Obstetrician-gynecologists' opinions and attitudes on the role of genetics in women's health. J Womens Health Gend Based Med 9 (2000) 873-879
73. Guttmacher A., Porteous M., and McInerney J. Educating health-care professionals about genetics and genomics. Nat Rev Genet 8 (2007) 151-157
74. Deftos L. The evolving duty to disclose the presence of genetic disease to relatives. Acad Med 73 (1998) 962-968
75. Friedman J., Blitzer M., Elsas II L., et al., Association of Professors of Human Genetics, Clinical Objectives Task Force. Clinical objectives in medical genetics for undergraduate medical students. Genet Med 1 (1998) 54-55
76. National Coalition for Health Professional Education in Genetics. Core competencies in genetics essential for all health-care professionals. Available at. http://www.nchpeg.org/core/Corecomps2005.pdf
77. March of Dimes. Genetics & your practice. Available at. http://www.marchofdimes.com/gyponline/index.bm2
78. Laskey S., Williams J., Pierre-Louis J., et al. Attitudes of African American premedical students toward genetic testing and screening. Genet Med 5 (2003) 49-54
79. Jain T., Missmer S., Gupta R., and Hornstein M. Preimplantation sex selection demand and preferences in an infertility population. Fertil Steril 83 (2005) 649-658
80. Wolfberg A. Genes on the Web-direct-to-consumer marketing of genetic testing. N Engl J Med 355 (2006) 543-545
81. Catz D., Green N., Tobin J., et al. Attitudes about genetics in underserved, culturally diverse populations. Community Genet 8 (2005) 161-172
82. Hipps Y., Roberts J., Farrer L., and Green R. Differences between African Americans and whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test 7 (2003) 39-44
83. Duran D. Lack of Hispanics' involvement in research-is it Hispanics or scientists?. Community Genet 1 (1998) 183-189
84. Jackson F. Scientific limitations and ethical ramifications of a non-representative Human Genome Project: African American response. Sci Eng Ethics 4 (1998) 155-170
85. Hoffman E., and Slade M. Ideas & trends in summary; sickle cell cadets won't be barred. New York Times (February 8, 1981)
86. Air force academy sued over sickle cell policy. New York Times (January 4, 1981)
87. Beene-Harris R., Wang C., and Bach J. Barriers to access: Results from focus groups to identify genetic service needs in the community. Community Genet 10 (2007) 10-18
88. Farmer J., and Chittams J. Professional status survey 2000. Perspect Genet Couns Suppl 22 (2000) S1-S12
89. US Dept of Justice. Americans with disabilities act. Available at. http://www.usdoj.gov/crt/ada/adahom1.htm
90. US Dept of Health and Human Services. Health insurance portability and accountability act of 1996. Available at. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf
91. Slaughter L. Your genes and privacy. Science 316 (2007) 797
92. Robbins L. In Curry, Knicks have a new center and a test case in medical ethics. New York Times (October 15, 2005)